320 related articles for article (PubMed ID: 28776922)
1. Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.
Craig CM; Liu LF; Nguyen T; Price C; Bingham J; McLaughlin TL
Diabetes Obes Metab; 2018 Feb; 20(2):352-361. PubMed ID: 28776922
[TBL] [Abstract][Full Text] [Related]
2. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.
Craig CM; Liu LF; Deacon CF; Holst JJ; McLaughlin TL
Diabetologia; 2017 Mar; 60(3):531-540. PubMed ID: 27975209
[TBL] [Abstract][Full Text] [Related]
3. Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide (exendin 9-39) for treatment of post-bariatric hypoglycaemia.
Tan M; Lamendola C; Luong R; McLaughlin T; Craig C
Diabetes Obes Metab; 2020 Aug; 22(8):1406-1416. PubMed ID: 32250530
[TBL] [Abstract][Full Text] [Related]
4. A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia.
Lobato CB; Pereira SS; Guimarães M; Hartmann B; Wewer Albrechtsen NJ; Hilsted L; Holst JJ; Nora M; Monteiro MP
Front Endocrinol (Lausanne); 2020; 11():608248. PubMed ID: 33424773
[TBL] [Abstract][Full Text] [Related]
5. Postprandial hypoglycaemia after Roux-en-Y gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide.
Øhrstrøm CC; Worm D; Højager A; Andersen D; Holst JJ; Kielgast UL; Hansen DL
Diabetes Obes Metab; 2019 Sep; 21(9):2142-2151. PubMed ID: 31144430
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
[TBL] [Abstract][Full Text] [Related]
7. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.
Salehi M; Gastaldelli A; D'Alessio DA
Gastroenterology; 2014 Mar; 146(3):669-680.e2. PubMed ID: 24315990
[TBL] [Abstract][Full Text] [Related]
8. Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia.
Mulla CM; Goldfine AB; Dreyfuss JM; Houten S; Pan H; Pober DM; Wewer Albrechtsen NJ; Svane MS; Schmidt JB; Holst JJ; Craig CM; McLaughlin TL; Patti ME
Obes Surg; 2019 Jul; 29(7):2092-2099. PubMed ID: 30976983
[TBL] [Abstract][Full Text] [Related]
9. Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass.
Tharakan G; Behary P; Wewer Albrechtsen NJ; Chahal H; Kenkre J; Miras AD; Ahmed AR; Holst JJ; Bloom SR; Tan T
Eur J Endocrinol; 2017 Dec; 177(6):455-464. PubMed ID: 28855269
[TBL] [Abstract][Full Text] [Related]
10. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
11. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects.
Barrington P; Chien JY; Tibaldi F; Showalter HD; Schneck K; Ellis B
Diabetes Obes Metab; 2011 May; 13(5):434-8. PubMed ID: 21251179
[TBL] [Abstract][Full Text] [Related]
12. Differential effect of endogenous glucagon-like peptide-1 on prandial glucose counterregulatory response to hypoglycaemia in humans with and without bariatric surgery.
Honka H; Gastaldelli A; Pezzica S; Peterson R; DeFronzo R; Salehi M
Diabetes Obes Metab; 2024 Jun; 26(6):2476-2486. PubMed ID: 38558527
[TBL] [Abstract][Full Text] [Related]
13. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S
Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780
[TBL] [Abstract][Full Text] [Related]
14. Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: A single-blind, randomized controlled trial.
Lipš M; Mráz M; Kloučková J; Kopecký P; Dobiáš M; Křížová J; Lindner J; Diamant M; Haluzík M
Diabetes Obes Metab; 2017 Dec; 19(12):1818-1822. PubMed ID: 28581209
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
[TBL] [Abstract][Full Text] [Related]
16. Canagliflozin or acarbose versus placebo to ameliorate post-bariatric hypoglycaemia - The HypoBar I randomized clinical trial protocol.
Lobato CB; Winding CT; Bojsen-Møller KN; Martinussen C; Veedfald S; Holst JJ; Madsbad S; Jørgensen NB; Dirksen C
Diabet Med; 2024 Jun; 41(6):e15320. PubMed ID: 38551152
[TBL] [Abstract][Full Text] [Related]
17. Nutrient re-routing and altered gut-islet cell crosstalk may explain early relief of severe postprandial hypoglycaemia after reversal of Roux-en-Y gastric bypass.
Svane MS; Toft-Nielsen MB; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S; Bojsen-Møller KN
Diabet Med; 2017 Dec; 34(12):1783-1787. PubMed ID: 28782840
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 (GLP-1) receptors are not overexpressed in pancreatic islets from patients with severe hyperinsulinaemic hypoglycaemia following gastric bypass.
Reubi JC; Perren A; Rehmann R; Waser B; Christ E; Callery M; Goldfine AB; Patti ME
Diabetologia; 2010 Dec; 53(12):2641-5. PubMed ID: 20835917
[TBL] [Abstract][Full Text] [Related]
19. Postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: an update.
Øhrstrøm CC; Worm D; Hansen DL
Surg Obes Relat Dis; 2017 Feb; 13(2):345-351. PubMed ID: 27865808
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
